Compare TSBK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | STRO |
|---|---|---|
| Founded | 1915 | 2003 |
| Country | United States | United States |
| Employees | N/A | 128 |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.0M | 332.8M |
| IPO Year | 1997 | 2018 |
| Metric | TSBK | STRO |
|---|---|---|
| Price | $46.45 | $20.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 30.0K | ★ 257.1K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.92 | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.96 | $0.72 |
| 52 Week High | $49.38 | $43.85 |
| Indicator | TSBK | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 38.63 |
| Support Level | $37.50 | $18.74 |
| Resistance Level | $49.38 | $26.35 |
| Average True Range (ATR) | 1.20 | 1.39 |
| MACD | -0.13 | 0.07 |
| Stochastic Oscillator | 33.96 | 25.94 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.